Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations

This study has been completed.
Information provided by (Responsible Party):
Array BioPharma Identifier:
First received: May 2, 2011
Last updated: February 11, 2016
Last verified: February 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2013
  Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)